← Back to Search
Liposomal Doxorubicin In The Treatment Of Breast Cancer Patients: A Review
J. Lao, J. Madani, T. Puértolas, María Álvarez, A. Hernandez, R. Pazo-Cid, Á. Artal, A. Antón Torres
Published 2013 · Medicine
Download PDFAnalyze on Scholarcy
Drug delivery systems can provide enhanced efficacy and/or reduced toxicity for anticancer agents. Liposome drug delivery systems are able to modify the pharmacokinetics and biodistribution of cytostatic agents, increasing the concentration of the drug released to neoplastic tissue and reducing the exposure of normal tissue. Anthracyclines are a key drug in the treatment of both metastatic and early breast cancer, but one of their major limitations is cardiotoxicity. One of the strategies designed to minimize this side effect is liposome encapsulation. Liposomal anthracyclines have achieved highly efficient drug encapsulation and they have proven to be effective and with reduced cardiotoxicity, as a single agent or in combination with other drugs for the treatment of either anthracyclines-treated or naïve metastatic breast cancer patients. Of particular interest is the use of the combination of liposomal anthracyclines and trastuzumab in patients with HER2-overexpressing breast cancer. In this paper, we discuss the different studies on liposomal doxorubicin in metastatic and early breast cancer therapy.
This paper references
Is this a practical approach?
R. Wallace (2001)
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II).
M. S. Rosati (2011)
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
Adjuvant Trastuzumab in HER 2-Positive Breast Cancer
D. Slamon (2011)
G. Roul (2009)
The Treatment of Breast Cancer Using Liposome Technology
S. Brown (2012)
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.
D. Rayson (2012)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II
J. Sparano (2009)
Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity.
A. P. Launchbury (1993)
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
G. Batist (2006)
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
L. Gianni (1997)
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth
R. Tolhurst (2010)
A phase I/II trial of nonpegylated liposomal doxorubicin, docetaxel, and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer
D Amadori (2011)
A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
S. Paliwal (2010)
Application of Nanotechnology in Cancer Therapy and Imaging
X. Wang (2008)
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
M. Martín (2011)
TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis
M. Theodoulou (2002)
Malignant tumors of the breast, " in De Vita, Hellman and Rosenberg's Cancer, Principles & Practice of Oncology
H J Burstein (2011)
Proceedings of the American Society of Clinical Oncology
J. Korinek (1982)
Preclinical development: tissue distribution of doxorubicin (DOX) and TLC D-99 and conventional doxorubicin Data from the Registration dossier
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Detection of Early Anthracycline Cardiotoxicity by Monitoring the Peak Filling Rate
W. Ganz (1993)
Liposomes. Opportunities in drug delivery.
T. Allen (1997)
Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
T. Elbayoumi (2008)
Side effects of adjuvant treatment of breast cancer.
C. Shapiro (2001)
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
D. Northfelt (1996)
Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
H. Gogas (2002)
Phase III trial of liposomal doxorubicin and ciclophosphamide compared with epirrubicin and ciclophosphamide as first-line therapy for metastasic breast cancer
S. Chan (2004)
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2010)
Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
J. Cortés (2009)
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A. Gordon (2001)
Effects of Polyethyleneglycol Chain Length and Phospholipid Acyl Chain Composition on the Interaction of Polyethyleneglycol-phospholipid Conjugates with Phospholipid: Implications in Liposomal Drug Delivery
F. Bedu-Addo (2004)
Adjuvant trastuzumab in HER2-positive breast cancer.
D. Slamon (2011)
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
M. Pegram (2004)
Malignant tumors of the breast
Audenino Rg (1960)
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
D. Drummond (1999)
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
E. Curtit (2011)
Effects of Drug Hydrophobicity on Liposomal Stability
D. R. Khan (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
A. Gennari (2008)
stuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer : phase II study of the hellenic cooperative oncology group ( HeCOG ) with biomarker evaluation
I. Kostopoulos Christodoulou (2009)
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
S. Chia (2006)
Preclinical development: tissue distribution of doxorubicin (DOX) and TLC D-99 and conventional doxorubicin
GEICAM 2003-03 study
Primary chemotherapy for locally advanced breast cancer (LABC) with gemcitabine (G) as prolonged infusion, liposomal doxorubicin (M) and Docetaxel (T): results of a phase I trial
K. Possinger (1971)
Prevention Strategies for Mycobacterium avium-intracellulare Complex (MAC) Infection
D. L. Cohn (2012)
Cardiac toxicity 4 to 20 years after completing anthracycline therapy.
L. Steinherz (1991)
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
A. Antón (2009)
A phase I/II trial of nonpegylated liposomal doxorubicin, docetaxel, and trastuzumab as first-line treatment inHER-2-positive locally advanced or metastatic breast cancer
D. Amadori (2011)
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
M. Venturini (2010)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198
A. Wolff (2010)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
[Malignant tumors of the breast].
R. Audenino (1960)
Anthracycline cardiomyopathy monitored by morphologic changes.
M. Billingham (1978)
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2006)
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
C. Rochlitz (2011)
Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet.
A. Gabizon (2001)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
Targeted drug delivery utilizing protein-like molecular architecture.
E. Rezler (2007)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
M. Untch (2010)
Preclinical development : tissue distribution of doxorubicin ( DOX ) and TLC D - 99 and conventional doxorubicin
D. D. Von Hoff
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
R. Krishna (1999)
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
E. Andreopoulou (2007)
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.
C. Shapiro (1998)
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
D. Amadori (2011)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans.
M. Stoddard (1992)
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer Journal of Drug Delivery 11 previously treated with adjuvant
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
E. Alba (2010)
Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
C. Christodoulou (2009)
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
P. Schmid (2008)
Malignant tumors of the breast Hellman and Rosenberg's Cancer, Principles & Practice of Oncology
H J Burstein (2011)
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.
A. Antón (2011)
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial
E. Stickeler (2008)
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
S. Chan (2004)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
Molecular portraits of human breast tumours
C. Perou (2000)
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Z. Symon (1999)
Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes.
Jie Gao (2009)
This paper is referenced by
Drug delivery: advancements and challenges
Narinder Singh (2017)
Selenoesters and Selenoanhydrides as Novel Agents Against Resistant Breast Cancer
A. Csonka (2019)
Building SuperModels: emerging patient avatars for use in precision and systems medicine
Sherry-Ann Brown (2015)
Immunotoxicity Considerations for Next Generation Cancer Nanomedicines
Gary Hannon (2019)
Nanooncology: The future of cancer diagnosis and therapy
A. Thakor (2013)
Ex Vivo Cardiotoxicity of Antineoplastic Casiopeinas Is Mediated through Energetic Dysfunction and Triggered Mitochondrial-Dependent Apoptosis
C. Silva-Platas (2018)
Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity
F. Yang (2017)
Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors
Jaydev Upponi (2014)
Controlled Drug Release and Cytotoxicity Studies of Beta-Lapachone and Doxorubicin Loaded into Cyclodextrins Attached to a Polyethyleneimine Matrix
A. Kowalczyk (2020)
Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
S. Rajappa (2018)
A novel approach to a controlled opening of liposomes.
A. Yaroslavov (2020)
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
K. Miller (2016)
Liposomal formulations of amphotericin B: differences according to the scientific evidence.
J. Azanza (2015)
Liquid formulation containing doxorubicin-loaded lipid-core nanocapsules: Cytotoxicity in human breast cancer cell line and in vitro uptake mechanism.
Michelli B. Antonow (2017)
Prevention of paclitaxel-induced neuropathy by formulation approach.
X. Zang (2019)
A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer.
A. Shafei (2017)
A Review- Emerging Use of Nano-Based Carriers in Diagnosis and Treatment of Cancer-Novel Approaches
Yaqub Khan (2015)
Reinforcement learning-driven de-novo design of anticancer compounds conditioned on biomolecular profiles
J. Born (2019)
Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.
E. Tahover (2015)
In silico and molecular validation of identified putative genes and functional analysis of a N K G2D ligand as a breast cancer biomarkers
H. A. Bankole (2015)
Novel mesoporous nanoparticles for the targeted delivery of anticancer agents to estrogen receptor overexpressing breast cancer
C. Day (2018)
2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ0814061), a novel microtubule inhibitor, evokes G2/M cell cycle arrest and apoptosis in human breast cancer cells.
Jingwen Xu (2016)
The lysosomal TRPML1 channel promotes breast cancer survival by supporting mitochondrial function and cellular metabolism
S. Almasi (2020)
THE ROLES OF MALT1 IN NF-κB ACTIVATION AND SOLID TUMOR PROGRESSION
Deng Pan (2016)
Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
P. Vici (2014)
Role of a novel benzoxazine derivative in the chemosensitization of colon cancer
Rejitha Suraj (2017)
BP-C1 in treatment of patients with stage IV breast cancer: A randomized, double-blind, placebo-controlled multicenter study and additional open-label treatment phase.
S. Larsén (2015)
Incorporation of Naked Peptide Nucleic Acids into Liposomes Leads to Fast and Efficient Delivery.
C. Avitabile (2015)
Expression de protéines par voie " cell-free " : de la régulation in vitro aux protéoliposomes
G. Hansen (2015)
Comparison of therapeutic efficacy of lipo-doxorubicin and doxorubicin in treating bladder cancer
D. Yu (2017)
Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment
P. Carron (2014)
Liposomes as nanomedical devices
G. Bozzuto (2015)See more